> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Recursion Cuts Quarterly Loss To $119.0 Million, Sees Cash Lasting Into 2029
- URL: https://www.bullished.co/recursion-cuts-quarterly-loss-to-119-0-million-sees-cash-lasting-into-2029-d85dbb77/
- Published: 2026-11-02T21:55:52.000Z
- Updated: 2026-11-02T21:55:52.000Z
- Description: The AI drug developer's revenue hit $18.6 million on a Sanofi milestone, and it named pharma veteran Fred Hassan chair.
- Author: Matteo Parrino
- Tags: SEC Filings, RXRX, Industry: Healthcare

[Recursion Pharmaceuticals](https://www.bullished.co/tag/rxrx/), which uses artificial intelligence and automated labs to discover and develop medicines, [narrowed its third-quarter net loss to $119.0 million](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/exhibit991-q0326.htm?ref=bullished.co), from $162.3 million a year earlier, and said its cash should last into 2029\. The company reported the results Monday alongside a new board chair and fresh data on its lead drug candidate.

## Revenue up, spending down

The loss works out to $0.22 per share, against $0.36 a year earlier. Revenue reached $18.6 million, versus $5.2 million in the third quarter of 2025, driven mainly by a $10.0 million milestone from Sanofi for an immunology small-molecule program.

Research and development spending fell to $99.1 million from $121.1 million. The company said the drop came mainly from $22.8 million of one-time in-process research costs, tied to buying full rights to its ENPP1 inhibitor REC-102 from a joint venture with Rallybio, that hit the year-earlier quarter and did not recur. General and administrative expense fell to $32.6 million from $41.6 million.

Net cash used in operations was $77.4 million, down from $117.4 million.

## Cash into 2029

Cash and restricted cash stood at $561.5 million on September 30\. Adding about $187.2 million in net proceeds from an underwritten offering completed October 16, pro forma cash was about $748.7 million. On current plans and with no further financing, Recursion expects that to fund it into 2029.

It reiterated 2026 cash operating expense guidance of less than $375 million and set 2027 guidance at less than $360 million. For the first nine months of 2026, that measure was $271.5 million, against $323.2 million a year earlier.

## Sanofi option and a new chair

Sanofi optioned the first development candidate from its collaboration with Recursion, a potential first-in-class oral immunology drug that Sanofi plans to take into Phase 1 in 2027\. The $10 million payment brings total upfront and milestone payments from Sanofi to $144 million, with more than $300 million in further milestones possible.

Recursion's board [appointed Fred Hassan chair](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/rxrx-20261031.htm?ref=bullished.co), effective October 31, expanding the board from nine to ten seats. Hassan previously ran Schering-Plough and Pharmacia, and is lead independent director at BridgeBio Pharma. Rob Hershberg said he will stay on the board.

## REC-4881 polyp data

At a medical meeting in Denver, Recursion [presented updated results](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/exhibit993-cgapr.htm?ref=bullished.co) for REC-4881 in familial adenomatous polyposis, an inherited condition with no approved drug therapies. After 12 weeks, 13 of 15 adults had less total polyp burden, with a 47% median reduction. Twelve weeks after stopping treatment, 11 of 13 evaluable patients remained below baseline.

The highest-grade treatment-related side effect was Grade 3 in four of 26 patients, with no Grade 4 or 5 events. The company anticipates starting a registrational trial in the second half of 2027, pending FDA discussions. It also reported early REC-1245 cancer data: three partial responses and an 11-of-12 disease control rate at doses of 45 mg or higher.

Recursion hosts a webinar at 8:00 a.m. ET Tuesday on the REC-4881 and REC-1245 data, and says it will give registrational trial details later this year.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — RECURSION PHARMACEUTICALS, INC. (RXRX)](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/rxrx-20261031.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991-q0326.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/exhibit991-q0326.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit992-pr.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/exhibit992-pr.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit993-cgapr.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/exhibit993-cgapr.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a3q26finaldeck\_rxrx.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000144/a3q26finaldeck%5Frxrx.htm?ref=bullished.co) — SEC EDGAR
- [Recursion Reports Third Quarter 2026 Financial Results and](https://www.globenewswire.com/news-release/2026/11/02/3393771/0/en/recursion-reports-third-quarter-2026-financial-results-and-extends-cash-runway-highlights-positive-clinical-data-in-rec-4881-and-rec-1245-sanofi-development-candidate-option-and-ap.html?ref=bullished.co) — globenewswire.com
- [New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep,](https://www.globenewswire.com/news-release/2026/11/02/3393764/0/en/new-phase-2-rec-4881-data-presented-at-cga-igc-show-deep-durable-polyp-burden-reductions-in-fap-with-activity-across-the-gi-tract-and-in-larger-higher-risk-polyps.html?ref=bullished.co) — globenewswire.com
- [Recursion Appoints Fred Hassan as Chair of the Board](https://www.globenewswire.com/news-release/2026/11/02/3393720/0/en/recursion-appoints-fred-hassan-as-chair-of-the-board.html?ref=bullished.co) — globenewswire.com

### More on Recursion Pharmaceuticals

- [Recursion Prices 61.54 Million New Shares At $3.25, Raising $200 Million Gross Before Fees](https://www.bullished.co/recursion-prices-61-54-million-new-shares-at-3-25-raising-200-million-gross-before-fees-08ed7018/)
- [Recursion Prices $200 Million Stock Sale At $3.25 A Share, Says Cash Now Lasts Into 2029](https://www.bullished.co/recursion-prices-200-million-stock-sale-at-3-25-a-share-says-cash-now-lasts-into-2029-00c3be82/)

[All Recursion Pharmaceuticals (RXRX) coverage →](https://www.bullished.co/tag/rxrx/)